Long-term results in hairy cell leukemia treated with 2-chlorodeoxyadenosine.

We treated 19 patients with hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine. 15 patients followed up at least 6 months were evaluated. The follow up period varied between 6 months and 37 months (median, 19 months). 8 patients were previously treated. The overall response in 15 evaluable HCL patients was 100%, with 87% complete hematological remissions including three patients with retroperitoneal and mediastinal lymphadenopathy and one patient with leukemic infiltrates of the cornea: 13% of patients achieved partial hematological remission. Soluble interleukin-2 receptor (sIL-2R) considered as a reliable non-invasive marker of HCL tumor burden dropped from the median of 1350 pM/ml (range 188 to 9000 pM/ml) to the median of 84.3 pM/ml (range 37 to 382 pM/ml) RdW which reflects the anisocytosis of red cells decreased after therapy from the median of 20.6% (range 13.1-25.0%) to the median of 13.7% (range 12.4-16.3%).

[1]  A. Rademaker,et al.  Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. , 1996, Blood.

[2]  D. Catovsky,et al.  2‐Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy , 1996, British journal of haematology.

[3]  G. Juliusson,et al.  Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Saven,et al.  Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. , 1994, Blood.

[5]  A. Delannoy,et al.  A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. , 1994, Leukemia.

[6]  A. Rademaker,et al.  Prospective evaluation of internal adenopathy in a cohort of 43 patients with hairy cell leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Zinzani,et al.  High complete remission rate in hairy cell leukemia treated with 2-chlorodeoxyadenosine. , 1993, Leukemia & lymphoma.

[8]  L. Peterson,et al.  Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. , 1993, Blood.

[9]  D. Carson,et al.  Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. , 1990, The New England journal of medicine.

[10]  F. Menestrina,et al.  Serum levels of soluble interleukin‐2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk , 1989, British journal of haematology.

[11]  J. S. Burke,et al.  The value of the bone-marrow biopsy in the diagnosis of hairy cell leukemia. , 1978, American journal of clinical pathology.

[12]  C. Berard,et al.  Splenic pseudosinuses and hepatic angiomatous lesions. Distinctive features of hairy cell leukemia. , 1977, American journal of clinical pathology.

[13]  J. Špaček,et al.  Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia. , 1996, Neoplasma.

[14]  J. Špaček,et al.  Long-term results in hairy cell leukemia treated by splenectomy. , 1993, Neoplasma.

[15]  A. Saven,et al.  2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and chronic lymphocytic leukemia. , 1993, Leukemia & lymphoma.